Compare MWH & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWH | MANE |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.3B |
| IPO Year | 2026 | 2026 |
| Metric | MWH | MANE |
|---|---|---|
| Price | $25.32 | $98.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $35.42 | ★ $83.33 |
| AVG Volume (30 Days) | ★ 1.8M | 552.8K |
| Earning Date | 03-19-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.86 | N/A |
| Revenue Next Year | $14.78 | N/A |
| P/E Ratio | $227.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.83 | $36.26 |
| 52 Week High | $48.40 | $131.24 |
| Indicator | MWH | MANE |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 40.60 |
| Support Level | $23.83 | $92.06 |
| Resistance Level | $30.74 | $116.86 |
| Average True Range (ATR) | 1.45 | 5.68 |
| MACD | -0.49 | -0.74 |
| Stochastic Oscillator | 12.00 | 18.89 |
SOLV Energy Inc is a provider of infrastructure services to the power industry, including engineering, procurement, construction, testing, commissioning, operations, maintenance and repowering. It specializes in designing, building and maintaining utility-scale solar and battery storage projects and related T&D infrastructure. The company's projects include: The Eldorado Solar Project, Gravel Pit Solar Project, and Vikings Solar-plus-Storage Project. It operates in one reportable segment which derives revenue through providing EPC, O&M and Development services throughout the Unites Sates. The company derives maximum of revenue from its EPC contracts.
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.